Bonfiglio Vincenza, Reibaldi Michele, Macchi Iacopo, Fallico Matteo, Pizzo Corrado, Patane Clara, Russo Andrea, Longo Antonio, Pizzo Alessandra, Cillino Giovanni, Cillino Salvatore, Vadalà Maria, Rinaldi Michele, Rejdak Robert, Nowomiejska Katarzyna, Toro Mario Damiano, Avitabile Teresio, Ortisi Elina
Department of Experimental Biomedicine and Clinical Neuroscience, Ophthalmology Section, University of Palermo, 90127 Palermo, Italy.
Department of Ophthalmology, University of Catania, 95100 Catania, Italy.
J Clin Med. 2020 May 21;9(5):1556. doi: 10.3390/jcm9051556.
The treatment for rhegmatogenous retinal detachment (RRD) is surgery, including pars plana vitrectomy (PPV) and scleral buckling (SB). Despite surgical advances, degeneration of the photoreceptors and post-operative complications, such as proliferative vitreoretinopathy (PVR), often occurs as the result of inflammation, preventing complete visual recovery or causing RRD recurrence. There is increasing evidence that in the presence of RRD, the activation of inflammatory processes occurs and the surgery itself induces an inflammatory response. This comprehensive review focuses on the use of different formulations of corticosteroids (CCS), as an adjunctive treatment to surgery, either PPV or SB, for RRD repair. The purpose was to review the efficacy and safety of CCS in improving functional and anatomical outcomes and in preventing postoperative complications. This review is organized according to the timing of CCS administration: preoperative, intraoperative, and postoperative. The evidence reviewed supported the role of the pre-operative use of CCS in the treatment of combined RRD and choroidal detachment (CD), reducing CD height. No solid consensus exists on intraoperative and postoperative use of CCS to treat and prevent postoperative complications. However, a large randomized clinical trial including more than 200 eyes suggested that oral prednisone after surgery decreases the rate of postoperative grade B PVR.
孔源性视网膜脱离(RRD)的治疗方法是手术,包括玻璃体切除术(PPV)和巩膜扣带术(SB)。尽管手术技术有所进步,但光感受器的退化以及术后并发症,如增殖性玻璃体视网膜病变(PVR),常因炎症而发生,妨碍了视力的完全恢复或导致RRD复发。越来越多的证据表明,在RRD存在的情况下,炎症过程会被激活,而且手术本身也会引发炎症反应。这篇综述聚焦于使用不同剂型的皮质类固醇(CCS)作为PPV或SB手术修复RRD的辅助治疗。目的是回顾CCS在改善功能和解剖学结果以及预防术后并发症方面的疗效和安全性。这篇综述根据CCS给药的时间进行组织:术前、术中和术后。所回顾的证据支持术前使用CCS在治疗合并RRD和脉络膜脱离(CD)时可降低CD高度。对于术中及术后使用CCS来治疗和预防术后并发症,目前尚无确凿的共识。然而,一项纳入200多只眼的大型随机临床试验表明,术后口服泼尼松可降低术后B级PVR的发生率。